Enviro has signed a conditional USD2m (approx. SEK19.
* Orders +62% y-o-y, BTB ~1.5x * Strength across segments, EBITA +15% vs.
Seafire delivered another quarter of strong earnings growth, despite temporary headwinds on organic ...
The FDA has started a follow-up inspection at NerPharMa, the main obstacle to approval of Dasynoc an...
Redeye provides an update on Xbrane following the Q3 report, which beat our estimates on shipments t...
On 30 October 2026, Smartbroker Holding AG adjusted its guidance for the 2026 financial year by way ...
Q3 NAV per share came in at € 33.84, up 0.6% qoq (Q2: € 33.
DMRE's Q3 results were largely in line with our expectations on rental income, while FFO was ahead o...
Westwing delivered its fifth consecutive quarter of growth, despite a soft consumer backdrop and hig...
Xplora's monthly subscriptions update shows that the Xplora Kids subscription base for October 2026 ...
Redeye provides its initial take on Navigo's Q3 2026 report.
Yesterday, BVB published preliminary Q1 figures, holding top-line stable yoy despite the 2025 Club W...
* Q3 in line, loss narrows vs. Q2 * FDA open to SPARKLE reread, endpoint still undefined * Building ...
Redeye provides an initial take following the release of Optomed’s Q3 2026 report.
BioInvent has set the subscription price in its rights issue of approximately SEK430m at SEK1 per sh...
Redeye updates on G5 Entertainment after Q3-results which showed a somewhat soft topline but strong ...
ProTrans-Young missed its primary endpoint, and the two-year data in the older cohort shows no widen...
* 13% organic growth (cons 5%), EBITA +47% vs cons * Sales beat in all regions, AI implementation de...
* Q3 earnings miss, but restructuring supports earnings recovery * We cut '27e-/'28e EBIT by 1.
* Orders +62% y-o-y and +50% vs. ABGSCe for 1.5x b-t-b * EBITA adj.